MDT

88.98

-0.82%↓

VEEV

281.01

-0.15%↓

A

115.98

-3.89%↓

WBA

11.5

+0.17%↑

HQY

97.6

+1.09%↑

MDT

88.98

-0.82%↓

VEEV

281.01

-0.15%↓

A

115.98

-3.89%↓

WBA

11.5

+0.17%↑

HQY

97.6

+1.09%↑

MDT

88.98

-0.82%↓

VEEV

281.01

-0.15%↓

A

115.98

-3.89%↓

WBA

11.5

+0.17%↑

HQY

97.6

+1.09%↑

MDT

88.98

-0.82%↓

VEEV

281.01

-0.15%↓

A

115.98

-3.89%↓

WBA

11.5

+0.17%↑

HQY

97.6

+1.09%↑

MDT

88.98

-0.82%↓

VEEV

281.01

-0.15%↓

A

115.98

-3.89%↓

WBA

11.5

+0.17%↑

HQY

97.6

+1.09%↑

Search

Heron Therapeutics Inc

Closed

SectorHealthcare

2.11 -2.76

Overview

Share price change

24h

Current

Min

2.1

Max

2.18

Key metrics

By Trading Economics

Income

-1M

2.6M

Sales

-1.9M

39M

Profit margin

6.773

Employees

122

EBITDA

-5M

3.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+186.7% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-16M

336M

Previous open

4.87

Previous close

2.11

News Sentiment

By Acuity

58%

42%

318 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Heron Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Jul 2025, 22:07 UTC

Major Market Movers

Trade Desk Rises on S&P 500 Inclusion

14 Jul 2025, 17:06 UTC

Major Market Movers

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 Jul 2025, 16:47 UTC

Acquisitions, Mergers, Takeovers

NatWest to Sell Stake in Permanent TSB

14 Jul 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14 Jul 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 Jul 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 Jul 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 Jul 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14 Jul 2025, 23:02 UTC

Earnings

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 Jul 2025, 23:02 UTC

Earnings

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 Jul 2025, 23:02 UTC

Earnings

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 Jul 2025, 23:01 UTC

Earnings

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 Jul 2025, 23:01 UTC

Earnings

China Vanke Expects 1H Loss to Widen >000002.SZ

14 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 Jul 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 Jul 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 Jul 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 Jul 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14 Jul 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 Jul 2025, 18:30 UTC

Acquisitions, Mergers, Takeovers

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 Jul 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 Jul 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 Jul 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 Jul 2025, 16:53 UTC

Hot Stocks

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 Jul 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 Jul 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

14 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 Jul 2025, 16:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer Comparison

Price change

Heron Therapeutics Inc Forecast

Price Target

By TipRanks

186.7% upside

12 Months Forecast

Average 6.25 USD  186.7%

High 9 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forHeron Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

2.0001 / 2.42Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

318 / 376 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.